Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.97 |
| ▸ | CHRNG | P07510 | 5/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.97 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.97 |
| ▸ | CHRND | Q07001 | 5/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL31748783 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL5075866 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL41602 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL1237221 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL29682406 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL300444 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL30679332 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL38777 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL29354885 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL12499296 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230140798-A1 | SYNTHETIC PEPTIDES DIRECTED AGAINST THE METABOTROPIC GLUTAMATE RECEPTOR 5 | LACTOCORE INC (US) | 2023-05-04 | — | — | US | claimed |
| EP-4135741-A1 | SYNTHETIC PEPTIDES FOR MODULATING THE METABOTROPIC GLUTAMATE RECEPTOR 5 | Lactocore, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| CN-115379847-A | Synthetic peptides for modulating metabotropic glutamate receptor 5 | 拉托科公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220175873-A1 | SYNTHETIC NEUROMODULATORY PEPTIDES | LACTOCORE, INC. | 2022-06-09 | — | — | US | claimed |
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12635957-B2 | Methods and kits for assessing neurological and ophthalmic function and localizing neurological lesions | NEW YORK UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-12629340-B2 | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | EMPROS PHARMA AB (SE) | 2026-05-19 | — | — | US | disclosed |
| US-20260124195-A1 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4729123-A2 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | Alto Neuroscience, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20220160683-A1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3977138-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | Quest Diagnostics Investments LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220071976-A1 | DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| US-11266633-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
| CN-114127554-A | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022040346-A1 | COMPOSITIONS AND METHODS FOR MOOD ENHANCEMENT | Epitracker, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3943076-A2 | A MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS | Empros Pharma AB (SE) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | SLC6A2 11/4885SLC6A3 1/4885ALDH1A1 2631/4885 |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | SLC6A2 14/4885SLC6A3 1/4885ALDH1A1 3201/4885 |
| US-20220071976-A1 | DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | SLC6A3, HTR6, SLC6A4 | SLC6A2 50/4885SLC6A3 1/4885ALDH1A1 3629/4885 |
| US-12635957-B2 | Methods and kits for assessing neurological and ophthalmic function and localizing neurological lesions | VGF, CHAT, PYGB | SLC6A2 309/4885SLC6A3 225/4885ALDH1A1 3981/4885 |
| US-20260124195-A1 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | IAPP, BDNF, ACHE | SLC6A2 57/4885SLC6A3 43/4885ALDH1A1 775/4885 |
| US-12629340-B2 | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | ACAT2, CEL, LIPC | SLC6A2 208/4885SLC6A3 445/4885ALDH1A1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.